Entercel

Enterome is a clinical-stage biopharmaceutical company pioneering the development of novel drugs based on its unique understanding of the gut microbiome-immune system axis. The company leverages its proprietary Mimicry platform to identify bacterial peptides that mimic human antigens, enabling the creation of targeted immunotherapies for cancer and inflammatory diseases. Its lead oncology programs, such as EO2401, are designed to trigger a potent and specific T-cell response against tumor cells. Additionally, Enterome is developing small molecule inhibitors and microbiome-derived proteins to address chronic autoimmune and inflammatory conditions. Headquartered in Paris, the company collaborates with major pharmaceutical partners to advance its diverse pipeline of innovative therapeutic candidates.